Impact of pregabalin reclassification as a controlled substance in Egypt on gabapentinoid and opioid utilization: A repeated cross-sectional study
Reclassifying pregabalin effectively reduced its utilization but prompted a shift to gabapentin use. Our findings highlight the complexity of drug policy interventions, underscoring the need for continuous monitoring to mitigate unintended substitution effects and better understand policy impacts of the treatment of pain.
Authors
- Katie J. Suda
- Araniy Santhireswaran (ORCID: https://orcid.org/0000-0003-2661-8557)
- Mohamed Ezzat Khamis Amin (ORCID: https://orcid.org/0000-0003-0404-2040)
- Jason R. Guertin (ORCID: https://orcid.org/0000-0003-1718-5307)
- Yilei Liu (ORCID: https://orcid.org/0000-0003-2640-7565)
- Mina Tadrous (ORCID: https://orcid.org/0000-0003-1911-6129)
- Shane LaRue (ORCID: https://orcid.org/0000-0003-1048-649X)
- Shanzeh Chaudhry (ORCID: https://orcid.org/0009-0006-7838-8836)
- Omneya Mohamed
Institutions
- East Sussex County Council (GB)
- University of Pittsburgh (US)
- University of Toronto (CA)
- AlAlamein International University (EG)
- The Quebec Population Health Research Network (CA)
- VA Pittsburgh Healthcare System (US)
- Université Laval (CA)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-12-05
- DOI
- https://doi.org/10.1371/journal.pone.0337833
- Primary Topic
- Opioid Use Disorder Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00